
TOO HIGH A PRICE: The Soaring Cost of Cancer Care





As cancer's economic burden grows, research shows that early detection can reduce the financial impact on employers, employees and their families.



The statistics are sobering: Today, annual cancer care costs in the U.S. exceed \$200 billion¹ and are increasing at a staggering rate, to a projected \$246 billion by 2030.² These spiraling figures impact everyone—patients, for whom out-of-pocket costs have increased steadily³, and employers, who now count cancer as the top driver of both their health care costs⁴ and long-term disability claims.⁵

In fact, while cancer accounts for only 1%⁶ of health insurance claims, it makes up 15%⁷ of overall employer healthcare spending. It's also the main source of catastrophic medical claims for self-funded employers—and has been every year since 2009.⁸





CANCER DRIVING HEALTH CARE COSTS FOR EMPLOYERS

Cancer treatment costs are increasing at a higher rate than treatment costs for any other disease.⁹ As a result, cancer has surpassed musculoskeletal diseases as the condition that is most contributing to rising employer healthcare costs:

83%

of employers count cancer among their top three healthcare cost drivers, compared to 76% that count musculoskeletal conditions.¹⁰

Cancer continues to be both the number one and two highest-cost condition among self-insured employers who buy stop-loss insurance to protect against unpredictably expensive health claims.¹¹

тор **2**



of employers said they have seen more late-stage cancers since 2021.⁴


Another forty-four percent anticipate seeing such an increase in the future, likely due to pandemic-related delays in care.⁴




What drives cancer costs?

These growing costs are partly due to the increasing incidence of cancer as America's population ages.¹¹ This demographic shift, however, is compounded by a steady rise in cancer diagnoses in people under age 50.¹² According to new research, rates of breast, colon, and other forms of cancer have dramatically spiked since 1990.¹²

Fortunately, as more people are diagnosed with cancer, they have a growing assortment of treatment options. But while oncology innovations such as genetic testing and targeted immunotherapies can be game changers, they come with large price tags. In fact, the average annual price of newly launched cancer drugs in the U.S. was \$283,000 in 2021, a 53% increase from 2017.¹³





53% 51NCE 2017

The average annual price of newly launched cancer drugs in the U.S. was \$283,000 in 2021, a 53% increase from 2017.¹³

Lost productivity also adds to cancer's economic burden for individuals, families and employers. Metastatic breast cancer alone costs the U.S. more than \$18 billion in lost productivity when patients are unable to work.¹⁴ Overall, patients diagnosed with late-stage cancers have significantly higher productivity losses when compared to early-stage cancers – including nearly double the number of sick days in the first year of diagnosis.¹⁵

What's more, even after an employee finishes surgery, radiation, chemotherapy, or immunotherapy, treatment isn't over. Cancer survivors often need follow-up treatment and imaging for months or years and may encounter long-term side effects as a result of treatment that require ongoing care.¹⁶

How employers can fight back

While employers might feel powerless in the face of these trends, closer analysis reveals one clear way to proactively address increasing costs: encourage screenings to promote early cancer detection. Early detection can dramatically reduce cancer's expense because cancers diagnosed at an earlier stage often require less intense, complicated and expensive treatment.¹⁵

The average cost to treat stage-1 breast cancer is about \$72,000, while stage-4 costs \$183,000.¹⁷

Overall, treatment for cancer that has metastasized costs employers an average of \$135,799 per year,¹⁸ which can be 2.7 times higher than the cost of treatment for stage-1 cancer. ¹⁹

Collectively, early detection is associated with potential annual cost savings of \$26 billion.²⁰

The problem? Only four kinds of cancer—breast, colon, lung and cervical—currently have an early detection screening recommended by the U.S. Preventitive Services Task Force (USPSTF).²¹ The cancer types that make up nearly three-quarters of employees' diagnosed cancers (including some of the deadliest, like pancreatic, liver, ovarian and stomach) have none.¹⁸ And a whopping 83% of employers' cancer claims that exceed \$100,000 are for cancers without recommended screenings.¹⁸

In addition to existing single cancer screenings, employers can also consider offering a multi-cancer early detection test for employees. For one such test, research shows that it can detect a cancer signal shared by more than 50 types of cancer with a simple blood draw, and modeled data suggests that early detection can create savings for both employers and employees.¹⁸

Cancer screening has been shown to save lives and offer the ability to begin treatment when costs may be less burdensome. By adding multi-cancer early detection tests to existing recommended screenings, both employers and employees can be more proactive in their approach to this terrible – and costly – disease.




FIGHTING FINANCIAL TOXICITY

Even as companies pay skyrocketing health care costs, they're not able to fully protect their employees from growing out-of-pocket expenses. As total cost of care has grown, privately insured patients have seen their out-of-pocket costs rise 15% for all cancers – to more than \$6,000 annually for breast, colorectal and lung cancer.²²

This has created growing adverse financial consequences, or financial toxicity, that has lasting consequences for cancer patients and their families.²² At its worst, financial toxicity can severely compromise patients' quality of life and lead to increased risk of bankruptcy and trouble paying for necessities.²³

Financial toxicity is a complicated problem that requires a multi-pronged response. Research shows that, in addition to financial navigation and counseling, screening practices can play a major role in reducing undue financial burden.²³





CITATIONS:

- Ryan D. Chow, Elizabeth H. Bradley, Cary P. Gross. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. J Natl Cancer Inst. 2022 Oct 6;114(10):1392-1399. doi: 10.1093/jnci/djac141. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2792761. para. 10. Published May 27, 2022. Accessed May 17, 2023.
- Angela B. Mariotto, Lindsey Enewold, et al. Medical Care Costs Associated with Cancer Survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1304-1312. doi: 10.1158/1055-9965.EPI-19-1534. https://aacrjournals.org/cebp/article/29/7/1304/72361/Medical-Care-Costs-Associated-with-Cancer. Volume 29, Issue 7. para 3. Published July 2020. Accessed May 17, 2023.
- 3. Ya-Chen Tina Shih, Ying Xu, et al. Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured. J Natl Cancer Inst. 2022 Oct 6;114(10):1392-1399. doi: 10.1093/jnci/djac141. Published October 2022. Accessed May 17, 2023.
- 4. Cancer Now Top Driver of Employer Health Care Costs, Says Business Group's 2023 Health Care Strategy and Plan Design Survey. Business Group on Health. https://www.
- businessgrouphealth.org/newsroom/news-and-press-releases/press-releases/2023-lehcspds. para 1, 2. Published August 23, 2022. Accessed May 17, 2023.
- Greg Breter. Top 10 causes of disability. Employee Benefit News. https://www.benefitnews.com/slideshow/top-10-causes-of-disability. para 4. Published May 25, 2018. Accessed May 17, 2023.
- Cancer and the Workplace: The Employer Perspective. The Northeast Business Group on Health. https://nebgh.org/wp-content/uploads/2015/10/CancerWorkplace_FINAL.pdf. page 6, para 2. Published October 2015. Accessed May 17, 2023.
- Costly conditions: Identifying and addressing top clinical cost drivers. Health Action Council, UnitedHealth Group. https://healthactioncouncil.org/getmedia/0f6eb427-7d56-4bc9-9c58-7475ace4d46e/2022-UHC_HAC_WhitePaper-Costly-Conditions_FINAL_page 1, see chart. Published February 2022. Accessed May 17, 2023.
- Brady Myers. Trends in the medical stop-loss market. Sun Life. MVP Roundtable. https://www.sunlife.com/content/dam/sunlife/regional/usa/documents/mvprt-thurs-recent-trends-inthe-medical-stop-loss-market.pdf. page 5, para 2. Published April, 2019. Accessed May 17,2023.
- Selena Gonzales and Cynthia Cox. What are recent trends in cancer spending and outcomes? Peterson-KFF. Health System Tracker. https://www.healthsystemtracker.org/chartcollection/recent-trends-cancer-spending-outcomes/#item-u-s-higher-average-disease-burden-lung-cancer para 18. February 10, 2016. Accessed May 22, 2023.
- 2023 Large Employers' Health Care Strategy and Plan Design Survey. Business Group on Health. https://ww2.businessgrouphealth.org/acton/attachment/32043/f-7262a100-64a9-4b52-96f4-37a344f9fc47/1/-/-/-/2023_PDS-Exec%20Summary.pdf. page 9, figure 9. Published 2022. Accessed May 17, 2023.
- Age and Cancer Risk. NIH. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/risk/age. para 1. Accessed May 17, 2023.
 Tomotaka Ugai, Naoko Sasamoto, et al. Is early-onset cancer an emerging global epidemic? Current evidence and future implications. Nat Rev Clin Oncol. 2022 Oct;19(10):656-673. doi:
- 10.1038/s41571-022-00672-8. https://www.nature.com/articles/s41571-022-00672-8. para 1, 2. Published Spetember 6, 2022. Accessed May 17, 2023.
- Deena Beasley. New U.S. cancer drug prices rise 53% in five years -report. https://www.reuters.com/business/healthcare-pharmaceuticals/new-us-cancer-drug-prices-rise-53-five-years-report-2022-11-02/. para 1. Published November 2, 2022. Accessed May 17, 2023.
- Conor Killmurray. Metastatic Breast Cancer Creates High Economic Burden Through Lost Productivity. curetoday.com. https://www.curetoday.com/view/metastatic-breast-cancercreates-high-economic-burden-through-lost-productivity. para 6. Published August 19, 2020. Accessed May 17, 2023.
- 15. Ze Cong, Oth Tran, James Nelson, Monica Silver and Karen Chung. Productivity Loss and Indirect Costs for Patients Newly Diagnosed with Early- versus Late-Stage Cancer in the USA: A Large-Scale Observational Research Study. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596506/. figure 6.
- 16. Follow-Up Medical Care. NIH. National Cancer Institute. https://www.cancer.gov/about-cancer/coping/survivorship/follow-up-care. para 16.
- 17. Helen Blumen, Kathryn Fitch, Vincent Polkus. Comparison of Treatment Costs for Breast Cancer, by Tumor Stage and Type of Service. Am Health Drug Benefits. 2016 Feb;9(1):23-32. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822976/pdf/ahdb-09-023.pdf
- 18. Analysis of MarketScan claims database completed by GRAIL, LLC, July 2022. Data on file GA-2022-0085
- November McGarvey, Matthew Gitlin, Ela Fadli, et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res. 2022;22(1):1155. doi: 10.1186/s12913-022-08457-6.
 https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-022-08457-6
- 20. Zura Kakushadze, Rakesh Raghubanshi, and Willie Yu. Estimating Cost Savings from Early Cancer Diagnosis. MDPI. https://www.mdpi.com/2306-5729/2/3/30 para 5. Published September 4, 2017. Accessed May 17, 2023.
- 21. US Preventive Services Task Force Recommended Screenings/p2/Table "Recommendations search results"/row 1,2; p3/row5,6,8.
- 22. New Study Shows Patients Paying More Out-of-Pocket Costs for Cancer Care. American Cancer Society. https://pressroom.cancer.org/OutofPocketCosts. para 1, 6. Published September 13, 2022. Accessed May 17, 2023.
- 23. Financial Toxicity Associated With Cancer Care—Background and Prevalence. NIH. National Cancer Institute. https://www.cancer.gov/about-cancer/managing-care/track-care-costs/ financial-toxicity-hp-pdq#_1. Section Etiology and Risks, para 5. Section Interventions Aimed at Reducing Financial Distress Among Cancer Patients, para 2.

©2023 GRAIL, LLC. ALL RIGHTS RESERVED | US-GA-2300234-1